Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


March 13, 2002 13 March, 2002

Pheromone Sciences Files with FDA for Marketing Approval of its Fertility Monitor


Pheromone Sciences (PHS:CDNX) today announced that it has filed a 510K application with the United States Food and Drug Administration seeking U.S. marketing approval for its lead product, the PSC Fertility Monitor(tm).

This application follows the recent announcement of positive results from a U.S. based multi-center clinical trial carried out at Duke University in Durham, N.C. under the direction of Dr. Arthur Haney and at The Women's Institute for Fertility, Endocrinology and Menopause affiliated with the Thomas Jefferson University Medical School in Philadelphia, PA., supervised by Dr. Stephen Corson.

Approval by the FDA of the Pheromone Sciences application would enable the Company to market the PSC Fertility Monitor(tm) across North America as well as in various other countries that use FDA guidelines as the primary element in granting marketing approvals. It is anticipated that a response to the Company's application will be received this summer.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Contact: Lorne Woods Judson Woods (800) 937-3095 lorne@judsonwoods.com 443 King Street East investor@pheromonesciences.com www.pheromonesciences.com

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.